Toxicology: Open Access
Open Access

Metal-on-metal hips; Metal ion measurement; Plasma; Whole blood; Interchangeability; Monitoring; Complications; Cobalt; chromium

Introduction

Metal-on-metal hip implants have been used in orthopedic surgery for many years due to their durability and stability. However, concerns have arisen regarding the release of metal ions into the bloodstream, leading to potential adverse reactions and complications. As a result, monitoring metal ion levels in patients with MoM hips has become crucial. Two common sample types used for metal ion measurement are plasma and whole blood. This article explores the interchangeability of plasma and whole blood metal ion measurement and their significance in monitoring patients with Mom hip implants [1].

The monitoring of metal ion levels in patients with MoM hips is crucial due to the potential adverse effects associated with elevated metal ion concentrations. High levels of cobalt and chromium ions in the bloodstream may indicate implant wear, corrosion, or adverse tissue reactions, such as pseudo tumor formation. Therefore, reliable and accurate measurement methods are essential for effective patient management.

Plasma metal ion measurement has been widely accepted as a standard approach in monitoring MoM hips. It offers advantages such as ease of collection and analysis, requiring smaller sample volumes and utilizing routine blood draws. Plasma measurements provide insights into the freely circulating metal ions in the bloodstream. Elevated plasma metal ion concentrations have been correlated with adverse clinical outcomes in patients with MoM hip implants [2].

However, the interchangeability of plasma measurements with whole blood measurements has gained attention in recent years. Whole blood metal ion measurement provides a more comprehensive evaluation, as it includes metal ions bound to red blood cells. This method offers insights into the total metal ion exposure within the bloodstream and may better reflect localized metal ion release and tissue effects.

The interchangeability of plasma and whole blood metal ion measurement has implications for clinical decision-making and the detection of potential complications in patients with MoM hips. Understanding the advantages and limitations of each method is crucial for optimizing monitoring protocols and ensuring timely intervention.

This article will discuss the existing research on the correlation between plasma and whole blood metal ion measurements, the challenges associated with each method, and the potential clinical implications. It will also emphasize the need for standardized guidelines to guide orthopedic surgeons and clinicians in selecting the most appropriate measurement method for monitoring metal ion levels in patients with MoM hip implants [3].

Plasma and whole blood metal ion measurement

Plasma and whole blood metal ion measurement techniques offer valuable insights into the performance and potential complications associated with MoM hip implants. These tests are conducted to assess metal ion concentrations, primarily cobalt and chromium, in the bloodstream. Elevated levels of these metal ions may indicate implant wear, corrosion, or adverse tissue reactions [4].

Plasma metal ion measurement involves collecting a blood sample and separating the liquid portion from the cellular components. This isolated plasma is then subjected to analysis, typically using techniques such as inductively coupled plasma mass spectrometry. Plasma measurements provide an assessment of the freely circulating metal ions.

On the other hand, whole blood metal ion measurement involves analyzing the metal ion concentrations in the entire blood sample, including both plasma and red blood cells. This measurement method accounts for the presence of metal ions bound to red blood cells and provides a comprehensive evaluation of metal ion levels within the bloodstream [5].

Interchangeability and clinical implications

The interchangeability of plasma and whole blood metal ion measurement is a topic of ongoing debate within the orthopedic community. While plasma measurement is widely accepted as a standard method, the use of whole blood measurements has gained attention in recent years.

Some studies suggest that plasma metal ion measurements can be directly correlated with whole blood measurements, implying that either sample type may be used interchangeably. These studies argue that the concentration of metal ions in plasma accurately reflects the overall concentration within the bloodstream, including both plasma and erythrocyte-bound ions [6].

Conversely, other research highlights the potential limitations of relying solely on plasma measurements. They argue that whole blood measurements provide a more comprehensive assessment, as they account for metal ions bound to red blood cells. Additionally, whole blood measurements may better represent the local tissue environment surrounding the implant, as erythrocytes can carry metal ions to distant sites.

The clinical implications of the interchangeability issue are significant. Accurate measurement of metal ion concentrations is crucial for timely intervention and management of patients with MoM hip implants. While plasma measurements offer a relatively straightforward and less invasive approach, they may underestimate the true metal ion burden in some cases.

In contrast, whole blood measurements, though more complex and requiring larger sample volumes, may provide a more accurate representation of the overall metal ion exposure. These measurements are particularly useful when assessing patients with a suspected adverse tissue reaction, where localized metal ion release may not be accurately reflected in plasma alone [7].

Discussion

The interchangeability of plasma and whole blood metal ion measurement in the monitoring of metal-on-metal hips is a topic of ongoing discussion within the orthopedic community. This discussion revolves around the question of whether plasma measurements alone are sufficient or if whole blood measurements should be incorporated for a more comprehensive evaluation.

Advocates for plasma metal ion measurement argue that it is a widely accepted and standardized method for monitoring patients with MoM hip implants. Plasma measurements provide a convenient and less invasive approach, as they require smaller sample volumes and can be easily obtained through a routine blood draw. Additionally, plasma measurements are considered more stable and less susceptible to factors such as hemolysis or clotting during sample collection and processing [8].

Furthermore, studies have shown a strong correlation between plasma metal ion concentrations and adverse clinical outcomes in patients with MoM hips. Elevated levels of cobalt and chromium in plasma have been associated with implant wear, corrosion, pseudo tumor formation, and tissue damage. Thus, proponents of plasma measurements argue that they are sufficient for assessing the systemic release of metal ions and detecting potential complications.

On the other hand, proponents of whole blood metal ion measurement highlight several advantages that support its inclusion in monitoring protocols. Whole blood measurements provide a more comprehensive evaluation of metal ion exposure, as they account for metal ions bound to red blood cells. This is particularly important because a significant portion of metal ions released from MoM hip implants can bind to erythrocytes and circulate within the bloodstream [9].

Whole blood measurements also offer potential insights into the local tissue environment surrounding the implant. Erythrocytes can carry metal ions to distant sites, and by analyzing metal ion concentrations in whole blood, it may be possible to identify localized metal ion release that is not accurately reflected in plasma measurements alone. This is particularly relevant in patients with suspected adverse tissue reactions, where localized metal ion release may be a key factor.

However, there are challenges associated with whole blood metal ion measurement. It requires larger sample volumes, which may pose logistical challenges, especially in routine monitoring scenarios. Additionally, whole blood measurements are more complex and may require specialized techniques for accurate analysis, such as highresolution ICP-MS.

Standardization and consensus regarding the interchangeability of plasma and whole blood metal ion measurements are lacking. The availability of reference ranges and cut-off values for whole blood measurements is limited, making it challenging to establish clear guidelines for clinical decision-making. More research is needed to determine the optimal timing and frequency of whole blood measurements and to establish their utility in predicting clinical outcomes and guiding treatment decisions.

Plasma and whole blood metal ion measurement in the monitoring of MoM hips remains a topic of discussion. While plasma measurements are widely accepted and offer convenience, whole blood measurements provide a more comprehensive assessment of metal ion exposure and the potential for localized effects. Standardization, further research, and consensus are needed to guide clinicians in selecting the most appropriate method for monitoring patients with MoM hip implants and detecting complications at an early stage [10].

Conclusion

Monitoring metal ion levels in patients with MoM hip implants is vital for the early detection of implant-related complications. While plasma metal ion measurements have traditionally been used, the interchangeability of plasma and whole blood measurements remains a subject of discussion.

Although plasma measurements offer ease of collection and analysis, whole blood measurements provide a more comprehensive assessment of metal ion concentrations. Considering the potential limitations of plasma measurements, it may be beneficial to incorporate whole blood measurements, especially in patients with suspected adverse tissue reactions.

Further research and consensus are needed to establish standardized guidelines regarding the interchangeability of plasma and whole blood metal ion measurements. This will enable orthopedic surgeons and clinicians.

Conflict of Interest

None

Acknowledgement

None

1. Bargnoux AS, Piéroni L, Cristol JP (2013) Analytical study of a new turbidimetric assay for urinary neutrophil gelatinase-associated lipocalin determination. Clin Chem Lab Med 51: 293-296.

Google Scholar, CrossRef , Indexed at

2. Westhoff JH, Tönshoff B, Waldherr S (2015) Urinary tissue inhibitor of metalloproteinase-2 insulin-like growth factor-binding protein 7 predicts adverse outcome in pediatric acute kidney injury. Plos One 10: 143-628.

Google Scholar, Crossref, Indexed at

3. Atzori L, Antonucci R, Barberini L, Griffin JL, Fanos V, et al. (2009) Metabolomics: a new tool for the neonatologist. J Matern Fetal Neonatal Med 22: 50-53.

Google Scholar, CrossRef , Indexed at

4. Evans GA (2000) Designer science and the ‘omic’ revolution. Nat Biotechnol 18: 127.

Google Scholar, Crossref, Indexed at

5. Palego L, Betti L, Giannaccini G (2015) Sulfur metabolism and sulfur-containing amino acids derivatives-part II: autism spectrum disorders, schizophrenia and fibromyalgia. Biochem Pharmacol 4: 159.

Google Scholar, Crossref, Indexed at

6. Granchi C, Roy S, Giacomelli C (2011) Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A as starvation agents against cancer cells. J Med Chem 54: 1599-1612.

Google Scholar, Crossref, Indexed at

7. Hou DY, Muller AJ, Sharma MD (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67: 792-801.

Google Scholar, Crossref, Indexed at

8. Stone TW, Stoy N, Darlington LG (2013) an expanding ranges of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34: 136-143.

Google Scholar, Crossref, Indexed at

9. Funke SA, Willbold D (2012) Peptides for therapy and diagnosis of Alzheimer's disease. Curr Pharm Des 18: 755-767.

Google Scholar, Crossref, Indexed at

10. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, et al. (2009) Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Chem Res 48:1981-198.

Google Scholar, Crossref, Indexed at